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doi:10.1016/j.kjms.2011.06.011Abstract The present study aimed to investigate the effects of N-methyl-D-aspartate (NMDA)-
type glutamate receptor agonist, NMDA, on anxiety-like behavior induced by d-opioid receptor
agents in rats, using the elevated plus maze instrument. The dorsal hippocampus (CA1) is known
to play an important role in anxiety formation and modulation. Bilateral administration of
different doses of d-opioid receptor agonist, [D-pen2,5] enkephalin acetate hydrate (1 mg/rat,
2 mg/rat, 5 mg/rat, and 10 mg/rat; 1 mL/rat; 0.5 mL/rat in each side), into CA1 area induced an
anxiolytic-like effect, demonstrated by substantial increases in the percent of open arm time
(OAT%) and percent of open arm entries (OAE%). Intra-CA1 injection of different doses of d-opioid
receptor antagonist, naltrindole hydrochloride (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat),
produced significant anxiogenic-like behavior. Furthermore, intra-CA1 administration of NMDA
glutamate receptor agonist, NMDA (0.125 mg/rat, 0.25 mg/rat, 0.5 mg/rat, and 0.75 mg/rat),
increased the OAT% and OAE%, indicating anxiolytic-like behavior. However, administration of
different doses of NMDA glutamatergic antagonist, MK801 (0.125 mg/rat, 0.25 mg/rat, 0.5 mg/
rat, and 1 mg/rat), showed no significant effect on the OAT% but decreased the OAE% signifi-
cantly. The ineffective dose of NMDA (0.125 mg/rat), when coadministered with enkephalin
(1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/rat), did not decrease the anxiety behavior significantly.
An effective dose of NMDA (0.5 mg/rat), in combination with different doses of naltrindole hydro-
chloride (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat), demonstrated no significant interac-
tion with the OAT%, OAE%, and locomotor activity. These results suggest that CA1 d-opioid and
NMDA glutamatergic systems modulate anxiety behaviors in a noninteractive manner.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.cience, Islamic Azad University, Karaj Branch, PO Box 31485-313, Karaj, Iran.
vier Taiwan LLC. All rights reserved.
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The hippocampus plays an important role in the modulation
and regulation of behaviors, such as learning and memory
[1]. In addition, role of dorsal hippocampus (CA1) in the
modulation of anxiety is crucial [2]. Previous studies have
shown that the serotonergic system of the dorsal hippo-
campus mediates anxiogenic responses, whereas the dorsal
hippocampal nicotinic cholinergic system mediates anxio-
lytic responses [2].
Glutamate, amain excitatory neurotransmitter of brain, is
of great significance in themodulation of behaviors bymeans
of several glutamate receptors. At least three subtypes of
excitatory amino acid receptors, named after their prefer-
ential agonists, that is, N-methyl-D-aspartate (NMDA), quis-
qualate, and kinate have been identified [3]. The NMDA
receptor, as an ionotropic glutamate receptor, plays an
important role in the modulation of behavioral effects of
glutamate. Studies demonstrated that the NMDA receptor is
involved in the control of anxiety-related behaviors. In
several studies conducted in animal models of anxiety, after
the administration of agonists of the NMDA receptor, behav-
ioral and anxiolytic effects have been reported [4].
Opioidpeptidesare involved indiverse functions, including
pain perception, respiration, homeothermy, nutrient intake,
and in immune response. Several researches have under-
scored the role of opioid receptors in regulating baseline
anxiety states and related behaviors [5]. Our previous study
showedthatdorsalhippocampalopioid receptors are involved
in the modulation of anxiety-associated behaviors [6].
Furthermore, neurotransmitter systems in different sites
across the central nervous system are also involved in the
modulation of opioid receptor agonisterelated effects on
anxiety and behaviors [7]. Recently, the regulating role of the
endogenous opioid system on emotional-like behavior has
been tested. Investigations on m- and d- but not k-opioid
receptor knockout mice have indicated that the basal levels
of anxiety in different models of anxiety are prone to change
[8]. Although the d-opioid receptor knockout mice showed
anxiogenic-like responses in theelevatedplusmaze (EPM)and
the light-dark box, the mice lacking m-opioid receptors
showed lower levels of anxiety in the EPM [8].
Interactions between opioidergic and glutamatergic
systems are reported in the different areas of the brain,
such as sensorimotor cortex [9], striatum [10], dorsal raphe
nucleus [11], and finally in spinal cord [12]. Opioids inhibit
glutamate release in rat periaqueductal gray cells, CA3
area [13], and also in the CA1 region of the hippocampus
[12]. Enkephalin and glutamate regulate the expression of
d-opioid receptors in rat cortical astrocytes [14]. Moreover,
the opioidergic system inhibits capsaicin-evoked release of
glutamate from rat spinal dorsal horn slices [15].
The opioidergic system inhibits Kþ-evoked glutamate
release from rat cerebrocortical slices [16]. Current
evidences suggest that long-term d-opioid receptor activa-
tion may cause alteration in the glial glutamate uptake
properties [17]. Furthermore, blocking of d-opioid recep-
tors induces an NMDA receptoredependent excitotoxicity in
anoxic turtle cortex [18]. On the other hand, some studies
have reported an interaction between d-opioid and NMDA
receptors in the development and maintenance of therepeated swim stress-induced thermal hyperalgesia [19]. In
the present study, possible interactions of the two systems
in the anxiety-like behaviors were investigated.
Methods
The study was carried out at the Biology Department of
Islamic Azad University, Karaj Branch, Karaj, Iran, between
December 2008 and June 2009. The University Ethics
Committee approved the research protocol. All the treat-
ments and behavioral tests were conducted between 3 PM
and 6 PM.
Animals
Male Wistar rats from Pasteur Institute (Tehran, Iran),
weighing 180e230 g at the time of surgery, were used. The
animals were housed four per cage in a room with
a 12:12 hour light/dark cycle (lights on 07:00 hours) and
controlled temperature (23 1C), and they had access to
food and water ad libitum and were allowed to adapt to the
laboratory conditions for at least 1 week before surgery. The
rats were handled about 3 minutes each day before behav-
ioral testing. All the experiments were performed between
12:00 hours and 15:00 hours, and each rat was tested only
once. Seven animals were used in each experiment.
Stereotaxic surgery and microinjections
The rats were anesthetized intraperitoneally with ketamine
hydrochloride (50 mg/kg) and xylazine (4 mg/kg) and placed
in a Stoelting stereotaxic instrument (Wood Dale, IL, USA).
A stainless steel guide cannula (22 gauge) was implanted in
the right and left CA1 regions according to Paxinos [20].
Stereotaxic coordinates for the CA1 regions were as follows:
3.8 mmposterior to bregma,2 mm lateral to themidline,
and 3 mm ventral of the dorsal surface of the skull. The
cannula was fixed to the skull with acrylic dental cement.
The animals were allowed 5 days before the test to recover
from surgery. The left and right CA1were infused bymeans of
an internal cannula (27 gauge), terminating 1 mm below the
tip of the guides, connected by polyethylene tubing to a 1-mL
Hamilton syringe (Bonaduz, GR, Switzerland). On each side,
0.5-mL solution was injected (1 mL/rat) over a 60-second
period. The inner cannula was left in place for an additional
60 seconds toallowdiffusionof the solutionand to reduce the
possibility of reflux. Intra-CA1 injections were made
5 minutes before testing.
Plus maze
This wooden, plus-shaped apparatus was elevated to the
height of 50 cm. This apparatus was composed of two
50 10-cm open arms and two 50 10 50-cm enclosed
arms, each with an open roof. The maze was placed in the
center of a quiet and dimly lit room. The rats’ behaviors
were directly observed using a mirror, suspended at an
angle above the maze. Behavioral data were collected by
an observer who quietly sat 1 m behind one of the closed
arms of the maze, using a time recorder. Five minutes after
Effects of NMDA and opioids of CA1 on anxiety 487their respective drug treatment, rats were placed individ-
ually in the center of the plus maze, facing one of the closed
arms. The observer measured (1) time spent in the open
arms, (2) time spent in the closed arms, (3) number of entries
into the open arms, and (4) number of entries into the
closed arms during the 5-minute test period. An entry was
defined as all four paws in the arm. The maze was cleaned
with distilled water after each rat was tested. For the
purpose of analysis, open arm activity was quantified as the
amount of time that the rat spent in the open arms relative
to the total amount of time spent in any arm (open/
total 100), and the number of entries into the open arms
was quantified relative to the total number of entries into
any arm (open/total 100). The total number of arms
entered, as well as the total number of closed arms entered,
was used as an index of general locomotor activity [21].Figure 1. A sample of the drug injection site in dorsal
hippocampus (CA1). The sections were taken through the brain
areas of cannulae placements, and the cannulae placements
were verified using the atlas of Paxinos.Drugs
The drugs used in the present study were [D-pen2,5]-
enkephalin acetate hydrate (d-opioid receptor agonist) and
naltrindole hydrochloride (d-opioid receptor antagonist)
(Tocris Co., Ballwin, MO, USA); NMDA (NMDA glutamatergic
receptor agonist); and MK801(NMDA glutamatergic receptor
antagonist) (Sigma Chemical Co., St. Louis, MO, USA).
Drug treatments
Experiment 1: effects of NMDA receptor agonist and
antagonist on anxiety behavior
Four groups of rats received bilateral dorsal hippocampus
injection (intra-CA1) of NMDA receptor agonist NMDA
(0.125 mg/rat, 0.25 mg/rat, 0. 5 mg/rat, and 0.75 mg/rat)
[22,23] and four other groups received NMDA receptor
antagonist MK801 (0.25 mg/rat, 0.5 mg/rat, 0.75 mg/rat, and
1 mg/rat) [22] and were compared with saline control group.
Experiment 2: effects of d-opioid receptor agonist and
antagonist on anxiety-like behavior
Four groups of rats received bilateral dorsal hippocampus
injection (intra-CA1) of selective d receptor agonist
enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/rat)
[24,25], and four other groups received d receptor antag-
onist naltrindole hydrochloride (0.25 mg/rat, 0.5 mg/rat,
1 mg/rat, and 2 mg/ratdintra-CA1) [26,27]. These rats were
thereafter compared with a saline control group.
Experiment 3: effects of NMDA in combination with
d receptor agonist on anxiety behavior
First,fivegroupsof rats received saline (1 mL/ratdintra-CA1).
Three minutes later, the first group received saline (1 mL/
ratdintra-CA1), and the other groups received four different
doses of enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/
ratdintra-CA1). Five other groups of rats received an intra-
CA1 injection of NMDA (0.125 mg/ratdintra-CA1) 3 minutes
before injection of saline (1 mL/ratdintra-CA1) or enkephalin
(1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/ratdintra-CA1).
Experiment 4: effects of NMDA in combination with
d receptor antagonist on anxiety behavior
The first five groups of rats received saline (1 mL/ratdintra-
CA1). Three minutes later, the first group received saline(1 mL/ratdintra-CA1), and the other groups received four
different doses of naltrindole (0.25 mg/rat, 0.5 mg/rat,
0.75 mg/rat, and 1 mg/ratdintra-CA1). Five other groups of
rats received an intra-CA1 injection of NMDA (0.5 mg/
ratdintra-CA1) 3 minutes before injection of saline (1 mL/
ratdintra-CA1) or naltrindole (0.25 mg/rat, 0.5 mg/rat,
0.75 mg/rat, and 1 mg/ratdintra-CA1).
Histology
Figure 1 shows the approximate point of the drug injection
in CA1. The histological results were plotted on the repre-
sentative section taken from the rat brain atlas of Paxinos
[20]. After the completion of behavioral testing, the
animals were killed with an overdose of chloroform. Ink
(0.5 mL of 1% aquatic methylene blue solution) was injected
into the guide cannulae using 27-gauge injection cannulae
that projected a further 0.5 mm ventral to the tip of the
guides to aid in histological verification. Brains were
removed and fixed in a 10% formalin solution for 48 hours
before sectioning. The sections were taken through the
brain areas of cannulae placements, and the cannulae
Figure 2. Effects of bilateral intra-CA1 injection of NMDA in
the elevated plus maze. Rats were treated with either saline
(1 mL/rat) or with NMDA (0.125 mg/rat, 0.25 mg/rat, 0.5 mg/rat,
and 0.75 mg/rat). Each bar is mean standard error of the
mean of percent of open arm time (A), percent of open arm
entries (B), or locomotor activity (C)dnZ 7. *p< 0.05,
**p< 0.01, and ***p< 0.001 when compared with the saline-
treated rats. CA1Z dorsal hippocampus region; NMDAZ
N-methyl-D-aspartate.
488 J. Solatiplacements were verified using the atlas of Paxinos. Data
from the rats with injection sites located outside the
hippocampal CA1 area were not used in the analyses. There
were seven rats with correct injection site per group.
Statistical analysis
Because data displayed normal distribution and homoge-
neity of variance, one-way analysis of variance (ANOVA)
was used for comparison among the effects of different
doses of drugs with vehicle. Two-way ANOVA was used for
the evaluation of interactions between drugs. In case the
difference was significant, the post hoc analysis (least
significant difference) was performed to assess specific
group comparisons. Differences with p< 0.05 between
experimental groups at each point were considered statis-
tically significant.
Results
Effects of NMDA receptor agonist and antagonist on
anxiety behavior
Figure 2 shows the effect of intra-CA1 injection of NMDA
(0.125 mg/rat, 0.25 mg/rat, 0.5 mg/rat, and 0.75 mg/rat) in
the EPM in rats. One-way ANOVA revealed that NMDA
increased the percent of open arm time (OAT%) [F (4,30)Z
12.636, p< 0.05] and percent of open arm entries (OAE%) [F
(4,30)Z 6.545, p< 0.05] at the doses of 0.25 mg/rat,
0.5 mg/rat, and 0.75 mg/rat, indicating the induction of
anxiolytic response by NMDA. No change in the locomotor
activity was observed [F (4,30)Z 0.690, p> 0.05].
However, the rats infused with MK801 (0.25 mg/rat,
0.5 mg/rat, 0.75 mg/rat, and 1 mg/ratdintra-CA1) showed
no significant decrease in OAT% [F (4,30)Z 2.294, p> 0.05]
but OAE% [F (4,30)Z 4.194, p< 0.05] decreased signifi-
cantly at doses 0.125 mg/rat and 0.25 mg/rat in comparison
with the saline-infused controls. No significant change in
the locomotor activity was observed [F (4,30)Z 1.814,
p> 0.05] (Fig. 3).
Effects of d-opioid receptor agonists and
antagonists on anxiety-like behavior
One-way ANOVA revealed that intra-CA1 injection of d-
opioid receptor agonist, enkephalin (1 mg/rat, 2 mg/rat,
5 mg/rat, and 10 mg/rat; 1 mL/rat) increased OAT% [F (3,24)
Z 4.421, p< 0.05] and OAE% [F (3,24)Z 5.599, p< 0.05] at
doses of 1 mg/rat, 2 mg/rat, and 5 mg/rat, indicating the
induction of anxiolytic effects. No significant change in
the locomotor activity was observed [F (3,24)Z 0.946,
p> 0.05] (Fig. 4).
The intra-CA1 infusions of d-opioid receptor antagonist
naltrindole hydrochloride decreased OAT% [F (4,30)
Z 5.532, p< 0.05] at doses of 0.5 mg/rat, 1 mg/rat, and
2 mg/rat, and decreased OAE% [F (4,30)Z 5.961, p< 0.05]
at doses of 0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat,
indicating the induction of anxiogenic effects by nal-
trindole. No significant change in the locomotor activity
was observed [F (4,30)Z 0.431, p> 0.05] (Fig. 5).Effects of enkephalin alone or with NMDA on
anxiety-like behavior
The effects of intra-CA1 injections of the d receptor
agonist, enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and
Figure 3. Effects of bilateral intra-CA1 injection of MK801 in
the elevated plus maze. Rats were treated with either saline
(1 mL/rat) or with MK801 (0.125 mg/rat, 0.25 mg/rat, 0.5 mg/
rat, and 1 mg/rat). Each bar is mean standard error of the
mean of percent of open arm time (A), percent of open arm
entries(B), or locomotor activity (C)dnZ 7. *p< 0.05, when
compared with the saline-treated rats. CA1Z dorsal hippo-
campus region.
Figure 4. Effects of bilateral intra-CA1 injection of
enkephalin in the elevated plus maze. Rats were treated with
either saline (1 mL/rat) or with enkephalin (1 mg/rat, 2 mg/rat,
5 mg/rat, and 10 mg/rat). Each bar is mean standard error of
the mean of percent of open arm time (A), percent of open arm
entries (B), or locomotor activity (C)dnZ 7. *p< 0.05 and
**p< 0.01, when compared with the saline-treated rats.
CA1Z dorsal hippocampus region.
Effects of NMDA and opioids of CA1 on anxiety 48910 mg/rat; 1 mL/rat) and NMDA (0.125 mg/rat), on the
response induced by enkephalin are shown in Fig. 6. Two-
way ANOVA indicated that the combination of enkephalin
(Factor A) with NMDA (Factor B) showed no interactions for
OAT% [Factor A: F (4,60)Z 7.488, p< 0.001; Factor B: F
(1,60)Z 3.12, p> 0.05; Factor (A B): F (4,60)Z 0.068,
p> 0.05]; for OAE% [Factor A; F (4,60)Z 7.951, p< 0.001;
Factor B; F (1,60)Z 1.350, p> 0.05; Factor (A B): F (4,60)
Z 0.250, p> 0.05]; and for locomotor activity [Factor A: F
(4,60)Z 0.48, p> 0.05; Factor B: F (1,60)Z 2.14, p> 0.05;
Factor (A B): F (4,60)Z 0.930, p> 0.05].Effects of naltrindole alone or with NMDA on
anxiety-like behavior
Figure 7 shows the effects of intra-CA1 injections of the
d-opioid receptor antagonist naltrindole (0.25 mg/rat,
0.5 mg/rat, 0.75 mg/rat, and 1 mg/ratdintra-CA1) in the
presence or absence of NMDA (0.5 mg/rat) on anxiety-like
Figure 5. Effects of bilateral intra-CA1 injection of nal-
trindole in the elevated plus maze. Rats were treated with
either saline (1 mL/rat) or with naltrindole (0.25 mg/rat,
0.5 mg/rat, 1 mg/rat, and 2 mg/rat). Each bar is mean
standard error of the mean of percent of open arm time (A),
percent of open arm entries (B), or locomotor activity (C)d
nZ 7. *p < 0.05 and ** p < 0.01, when compared with the
saline-treated rats. CA1Z dorsal hippocampus region.
Figure 6. The effect of bilateral injection of enkephalin in
the presence or absence of NMDA in the elevated plus maze.
Rats were injected saline (1 mL/ratdintra-CA1) or enkephalin
(1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/ratdintra-CA1) 3
minutes after injection of either saline (1 mL/ratdintra-CA1) or
NMDA (0.125 mg/ratdintra-CA1). Each bar is mean standard
error of the mean of percent of open arm time (A), percent of
open arm entries (B), or locomotor activity (C)dnZ 7.
*p< 0.05, **p< 0.01, and ***p< 0.001 when compared with the
saline-treated rats. þp< 0.05 and þþp< 0.01 when compared
with the saline- and NMDA-treated rats. CA1Z dorsal hippo-
campus region; NMDAZ N-methyl-D-aspartate.
490 J. Solatibehavior. Two-way ANOVA showed no interactions between
the effects of naltrindole (Factor A) and NMDA (Factor B)
on OAT% [Factor A: F (4,60)Z 2.821, p< 0.05; Factor B: F
(1,60)Z 186.06, p< 0.001; Factor (A B): F (4,60)Z 0.25,
p> 0.05]; on OAE% [Factor A: F (4,60)Z 5.261, p< 0.001;
Factor B: F (1,60)Z 16 .068, p< 0.001; Factor (A B):F (4,60)Z 0.696, p> 0.05]; and on locomotor activity
[Factor A: F (4,60)Z 0.725, p> 0.05; Factor B: F (1,60)
Z 3.226, p> 0.05; Factor (A B): F (4,60)Z 0.984,
p> 0.05], indicating no interaction between naltrindole
and NMDA on anxiety-related behaviors. The post hoc
analysis showed that naltrindole induced anxiogenic-like
effects, and NMDA induced anxiolytic-like effects.
Discussion
In this study, effects of hippocampal NMDA glutamatergic
system and d-opioidergic receptor agents, and also the
possible interactions between these agents in the EPM were
investigated.
Figure 7. The effect of bilateral injection of naltrindole in
the presence or absence of NMDA in the elevated plus maze.
Rats were injected saline (1 mL/ratdintra-CA1) or naltrindole
(0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/ratdintra-CA1) 3
minutes after injection of either saline (1 mL/ratdintra-CA1)
or NMDA (0.5 mg/ratdintra-CA1). Each bar is mean standard
error of the mean of percent of open arm time (A), percent of
open arm entries (B), or locomotor activity (C)dnZ 7.
*p< 0.05, **p< 0.01, and ***p< 0.001 when compared with the
saline-treated rats. þp< 0.05 when compared with the saline-
and NMDA-treated rats. CA1Z dorsal hippocampus region;
NMDAZ N-methyl-D-aspartate.
Effects of NMDA and opioids of CA1 on anxiety 491The results obtained from the present study show that
intraedorsal hippocampus (intra-CA1) injection of NMDA
increased OAT% and OAE%, without any impairment in
locomotor functioning in the EPM, indicating the induction
of an anxiolytic response by NMDA. Thus, the involvement
of NMDA receptor mechanism of dorsal hippocampus in the
anxiety-like behavior of rats seems possible.
Several recent investigations about the neurobiology of
anxiety have highlighted the role of neurotransmitter
glutamate as an important element in anxiety and anxious
behavior. The effects of glutamate are mediated through
different combinations of ionotropic and metabotropic
glutamate receptors and potentially different subunit
combinations [28,29].Studies suggest that the hippocampus may be involved in
these anxiolytic-like actions of glutamatergic system,
because the intrahippocampal injections of LY354740, an
mGLU2/3 receptor agonist, produced anxiolytic-like effects
in rat models [30,31]. An investigation carried out by Linden
et al. [32] showed that the anxiolytic-like activity
of LY354740 was associated with the suppression of EPM-
induced c-Fos in the hippocampus of mice.
So far, many efforts have been made to develop
compounds that can modulate the function of NMDA
receptors by acting within the NMDA receptor complex.
Nonetheless, using NMDA antagonists appears to be greatly
hampered by their associated adverse effects on anxiety
because of interference with receptors throughout the
central nervous system and the body [28]. Our results
demonstrate that the NMDA receptor antagonist MK801
decreases OAE% without significant change in the OAT%
and locomotor activity, indicating an anxiogenic effect
by MK801, whereas the anxiolytic-like effects of NMDA
receptor antagonists have been exhibited in some previous
studies. Studies conducted by Jardim and Stephens
demonstrated that the systemic or intra-dorsolateral per-
iaqueductal gray administration of NMDA receptor antag-
onists produces anxiolytic-like effects in animal anxiety
models, such as the EPM, brain aversive electrical stimu-
lation, and the Vogel’s punished licking test [33,34].
Studies showed that the administration of antagonists of
NMDA and non-NMDA-type receptors into the basolateral
amygdala reduces anxiety in animal models [35]. There-
fore, it seems that the major target for systemic injections
is likely amygdala rather than the hippocampus region.
Moreover, controversial results obtained in different
investigations may be attributed to different sites of
injections or also the different animal models used.
Our results show that the NMDA antagonist, MK801, had
only partial effects on anxiety, whereas NMDA agonist
clearly affected anxiety-related behaviors. Because the
NMDA agonist is more effective than its antagonist, it might
be suggested that there is no active anxiety-related
endogenous NMDA receptor activity in the CA1.
Other parts of our experiments indicate that intra-CA1
injection of enkephalin increased both OAT% and OAE%
without locomotor impairment in the EPM, indicating
the induction of an anxiolytic response by enkephalin.
Furthermore, intra-CA1 administration of the d-receptor
antagonist naltrindole produced substantial anxiogenic-like
effects in the plus maze, without any effect on the loco-
motor activity. The data show that the opioid receptor
system in the hippocampus is involved in the anxiolytic-like
behavior.
The important role of the opioidergic system in the
modulation of anxiety has been shown recently [36].
Because opioid-deficient mice are more anxious than the
normal controls [37], the anxiety disorders may be related,
at least in part, to the deficiency of the endogenous opioid
system [36]. Also, d-opioid receptors have been associated
with anxiety and depression, because d agonists reduce the
immobility of the rats in the forced swimming test [38,39].
A study carried out by Filliol et al. demonstrated that
d-opioid receptor knockout mice show anxiogenic-like
response in the EPM and the light-dark box. However, the
mice lacking m-opioid receptors exhibit lower levels of
492 J. Solatianxiety in the EPM [8]. The study by Sher in 2001 [37]
showed that intracerebroventricular microinjections of
d-opioid receptor antagonist cause a significant anxiogenic
effect in mice [40].
None of the drugs used in the present study affected the
locomotor activity of the rats. Locomotor activity evalua-
tion was included primarily to ensure that the effects of the
drugs in the EPM test of anxiety could not be attributed to
their activity effects [41].
In conclusion, the results of the present study demon-
strate that the intrahippocampal injections of the NMDA
glutamatergic and the d-opioid receptor agents affected
anxiety behaviors in the rats. There was, however, no
interaction between the NMDA and the enkephalin.
Furthermore, the intra-CA1 injections of naltrindole and
NMDA showed no interaction between these agents in the
modulating effects of anxiety-related behavior. Although
interaction between the NMDA glutamatergic and opioi-
dergic systems in the modulation of emotional behaviors
has been reported in previous studies, our results show that
there are no significant interactions between the two
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